The 13 most recent market catalysts affecting $OMER, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 55
Omeros Corporation Grants Performance-Based Stock Options to CEO
Omeros Corporation has granted its CEO, Gregory A. Demopulos, a performance-based stock option award for up to 500,000 shares. This award is structured with four equal tranches tha…
Oct 16, 2026
Corporate Catalyst
Bearish
Impact 95
Omeros shares are trading lower after the company announced that the EMA’s CHMP issued a negative opinion on its marketing authorization application for narsoplimab in TA-TMA, following re-examination of its original negative opinion adopted in June 2026.
This is a major negative catalyst for Omeros as the EMA's CHMP has definitively rejected marketing authorization for narsoplimab in TA-TMA, even after re-examination. This decision…
Oct 16, 2026
Corporate Catalyst
Bearish
Impact 85
Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends
Omeros Corporation (OMER) is experiencing a significant negative impact due to the European Medicines Agency's (EMA) final rejection of narsoplimab for TA-TMA. This decision elimin…
Oct 16, 2026
Corporate Catalyst
Neutral
Impact 75
Omeros Receives EMA CHMP Negative Opinion On Its Marketing Authorization Application For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Omeros received a negative opinion from the EMA's CHMP for its drug narsoplimab (YARTEMLEA) for TA-TMA in Europe, following a re-examination. This is a significant setback as it bl…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 75
Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst
Cantor Fitzgerald upgraded Omeros Corp. (OMER) from Neutral to Overweight and reinstated a $22 price target, indicating a strong belief in the future performance of the company's d…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 75
Omeros shares are trading higher after Cantor Fitzgerald upgraded the stock from Neutral to Overweight rating and announced a $22 price target.
This headline represents a significant corporate catalyst for Omeros (OMER). An upgrade from Neutral to Overweight by a reputable firm like Cantor Fitzgerald, coupled with a substa…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 65
Cantor Fitzgerald Upgrades Omeros to Overweight, Announces $22 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders upgraded Omeros (OMER) from a 'Neutral' to an 'Overweight' rating and established a $22 price target. This upgrade signals a more o…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 75
Omeros shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline indicates a significant positive corporate catalyst for Omeros. Better-than-expected financial results typically lead to increased investor confidence, higher stock p…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 95
Why Omeros Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Omeros Corp. (OMER) experienced a significant pre-market surge due to reporting much better-than-expected second-quarter financial results, turning a projected loss into a profit a…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
12 Health Care Stocks Moving In Wednesday's After-Market Session
The filing details the after-market trading activity for a selection of healthcare stocks, highlighting both gainers and losers. The primary driver for several of these movements, …
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 75
Omeros shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline indicates a significant positive corporate catalyst for Omeros. Better-than-expected financial results typically lead to increased investor confidence, higher stock p…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 95
Omeros Q2 Adj. EPS $0.02 Beats $(0.27) Estimate, Sales $28.529M Beat $12.700M Estimate
Omeros reported a substantial beat on both its Q2 adjusted EPS and sales figures. The company's shift from a significant loss in the prior year to a profit, coupled with sales more…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 85
Omeros Announces CMS Grants New Technology Add-On Payment Status For YARTEMLEA, Providing Hospitals Up To $287,079 Per Eligible Medicare Inpatient Starting October 1
This news is a major positive catalyst for Omeros (OMER). The New Technology Add-On Payment (NTAP) status from CMS provides significant reimbursement, up to $287,079 per eligible M…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.